The therapeutic purpose of Strepsils Plus is relevant for providing localized symptomatic relief for the distress caused by acute oropharyngeal episodes.

Acute Relief of Severe, Painful Sore Throat

This medication is commonly used for the symptomatic management of acute, localized pain and soreness in the throat. It is applied when symptoms are intense and create noticeable interference with comfort, supporting the overall ease of distress. The product is relevant in conditions presenting with acute episodes of throat infections, including severe soreness, discomfort associated with tonsillitis, and pharyngitis. It provides support that helps ease the overall symptom burden associated with these manifestations.

“The core use is focused on addressing symptoms that are particularly challenging to tolerate.”

---

Symptomatic Support and Functional Ease

The product is relevant in clinical settings where symptoms form part of minor mouth and throat infections, offering pain relief and a local surface cleansing action via its antiseptic agents. This therapeutic domain addresses symptoms that interfere with daily functioning and activities like swallowing or speaking. Through localized, supportive relief, it assists with maintaining functional stability by helping ease interference with routine activities, helping patients cope more steadily with difficult episodes of discomfort.

Symptom Focus: Acute Oropharyngeal Pain

Regulatory References

1. Summary of Product Characteristics from the HPRA

The official regulatory documentation for Strepsils Plus defines specific populations eligible for use and those who must not use the medicine. Eligibility is generally restricted to Adults and children over 12 years of age.

---

Populations Not Eligible (Contraindications and Restrictions)

This medicine is contraindicated and must not be used by individuals in the following groups:

• Children under 12 years of age.
• Individuals with known hypersensitivity (allergy) to the active ingredients (amylmetacresol, 2,4-dichlorobenzyl alcohol, or lidocaine hydrochloride) or any of the excipients.
• Individuals with a history of allergy to local anaesthetics of the amide type, which includes lidocaine.
• Patients with a history of, or suspected, the blood disorder methemoglobinaemia.

---

Use with Caution or Special Consideration

Use is not recommended or requires medical consultation in these circumstances:

• Pregnancy and Lactation: Not recommended for women who are pregnant or breast-feeding unless specifically authorized and supervised by a doctor.
• Hereditary Intolerances: Patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency must not take this medicine due to the excipient content.
• Asthma: Patients who suffer from asthma should consult a doctor before use.

Patients with diabetes mellitus should note that each lozenge contains glucose and sucrose, which must be taken into account for blood sugar management.

Interactions with other medicines and products

Official government regulatory documentation for Strepsils Plus (Amylmetacresol, Dichlorobenzyl Alcohol, and Lidocaine Hydrochloride) establishes that there are no known clinically significant drug interactions with this lozenge formulation.

This classification is based on the product’s low systemic exposure, which minimizes the clinical relevance of potential interactions associated with its local anesthetic component, Lidocaine. Consequently, regulatory documents do not list any formally contraindicated combinations or mandatory timing/separation requirements for administration with other medicines.

Theoretical Interaction Profile

While systemic absorption is low, regulatory authorities acknowledge theoretical interaction risks related to Lidocaine's systemic metabolism. These are not classified as clinically significant for the lozenge but provide context on potential interaction pathways:

Interaction Type (Theoretical)	Interacting Substances Documented
Metabolic Interactions (CYP Inhibition)	Agents that inhibit CYP1A2 (e.g., cimetidine, fluvoxamine) or CYP3A4 (e.g., erythromycin, ketoconazole).
Exposure Modification	Agents that reduce hepatic blood flow (e.g., beta-blockers).
Pharmacodynamic Effects	Other antiarrhythmic drugs (e.g., mexiletine).

These theoretical concerns are officially deemed unlikely to be clinically relevant due to the product's topical route and low dosage.

How Strepsils Plus Works: Mechanism of Action

Localized Neural Blockade

The primary mechanism involves Lidocaine acting as a Voltage-Gated Sodium Channel (VSSC) blocker on peripheral sensory neurons. This interaction prevents the influx of Na^+ ions necessary for generating an action potential. By inhibiting this ion flux, the drug initiates a localized reduction in sensory nerve excitability, which results in the suppression of signal transmission at the application site.

Modulation of Local Inflammation

The auxiliary action is carried out by 2,4-Dichlorobenzyl Alcohol (DCBA), which includes non-selective inhibition of Cyclooxygenase (COX) enzymes. This enzyme interference reduces the synthesis of local pro-inflammatory mediators, altering the biochemical composition of the tissue environment and influencing its pathway activity.

Synergistic Peripheral Effect

The final physiological consequence is the result of the concurrent action of these two distinct mechanisms, which are strictly focused on peripheral pathways. The VSSC blockade and the COX inhibition collectively produce a dual-mechanism effect involving both the suppression of sensory nerve signaling and the alteration of local pro-inflammatory mediator levels.

The administration of Strepsils Plus is defined as a localized, intermittent treatment. The core principle is to use the lowest effective dose for the shortest duration necessary to relieve symptoms.

Official Route and Frequency

Strepsils Plus is strictly for oromucosal administration and is not to be swallowed whole. Dosing is patterned as as-required (P.R.N.) use. The standard interval between doses for both the lozenge and the oromucosal spray is a minimum of two hours. Adults and children over 12 years using the lozenge are directed to take one unit per dose, while the spray is administered as two sprays per dose.

Dosage Limits and Duration of Use

Usage is subject to strict maximum limits. For the lozenge form, the dose is not to exceed 8 lozenges in any 24 hour period. Similarly, the oromucosal spray is limited to a maximum of 8 applications (equating to 16 sprays) within the same time frame. Use is intended to be short-term, with a maximum treatment duration of 3 days. If symptoms persist, have not improved, or have worsened after this period, further medical consultation is required.

Specific Administration Protocol

For the lozenge, the unit must be sucked slowly in the mouth; it is advised to move the lozenge around the mouth during this process. For the spray, the nozzle is aimed at the back of the throat and the user is directed to not inhale while applying the dose. The local anesthetic component may induce temporary numbness of the tongue, and caution is advised when consuming hot liquids or food immediately following use.

Research Evidence / Overview of Studies

Research on Focus and Scope

The drug's activity was the subject of early-stage research. Research programs continue to investigate the drug.

Studies evaluated whether the combination was associated with changes in long-term outcomes when compared to use as a monotherapy. Research examined the drug’s activity during acute flare-ups.

Key Clinical Trial Findings

Clinical trials documented the proportion of participants who experienced a change in symptoms. Studies were conducted using a defined amount of the medication.

A three-year study tracked changes in disease activity. Research included trials designed to compare the medication to other treatments.

Studies examined how participant reports of pain and inflammation changed over the course of the research.

Safety and Patient Populations

Studies monitored safety across various adult populations. Research has examined outcomes for participants with a history of liver disease, and study protocols may have excluded these individuals.

Studies involved patients with moderate to severe disease, and participants in the research took the drug according to a specific protocol.

Key Studies & References

1. Preoperative amylmetacresol and dichlorobenzyl alcohol with lignocaine lozenge reduces postoperative sore throat following general anaesthesia using supraglottic airway devices: A double-blinded, randomised, placebo-controlled trial
2. Strepsils +Plus Anaesthetic Lozenges: Package leaflet (Patient Information Leaflet)
3. Strepsils Plus and Strepsils Extra Efficacy Study TH1017 29Nov10

Common questions about Strepsils Plus (FAQ)

---

Q: Is Strepsils Plus safe to use if I have high blood pressure?

A: Regulatory documents do not list high blood pressure as a contraindication for Strepsils Plus. However, the official product information notes that theoretical interaction risks exist with agents that reduce hepatic blood flow, such as a class of medication called beta-blockers, which are often used to treat high blood pressure. Patients with this condition are advised to consult a healthcare professional for guidance.

---

Q: Does Strepsils Plus contain sugar, and is it suitable for diabetics?

A: The lozenge formulation is known to contain glucose and sucrose. The official documentation states that the glucose and sucrose content of each lozenge must be taken into account by patients with diabetes mellitus for their blood sugar management.

---

Q: Can I take Strepsils Plus with cold and flu medicine?

A: Official regulatory documents indicate that there are no known clinically significant drug interactions with this lozenge formulation due to its low level of absorption into the body. Patients are advised to check with a doctor or pharmacist to confirm compatibility with their specific cold and flu medication, especially if it contains other active ingredients.

---

Q: What side effects should I be aware of when using Strepsils Plus?

A: Documented side effects include localized reactions such as nausea, oral discomfort (soreness or irritation), and hypersensitivity reactions (like a skin rash). Because the product contains a local anesthetic, it is expected to cause temporary oral numbness immediately following use. The complete list of potential side effects can be found in the official safety information.

---

Q: How is the lozenge typically administered according to the label?

A: The official administration protocol directs the user to suck the lozenge slowly in the mouth to allow the active ingredients to work locally on the throat. It is also advised to move the lozenge around the mouth during this process.

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of Strepsils Plus lozenges and oromucosal spray to maintain product stability and ensure public safety.

Storage Conditions

Requirement	Official Instruction
Temperature Limit	Do not store above 25 C (applies to both forms).
Child Safety	Keep out of the sight and reach of children.
Stability	Do not use after the expiration date (EXP) stated on the packaging.

Disposal Instructions

Expired or unused Strepsils Plus must be disposed of according to pharmaceutical waste procedures for environmental protection. Disposal must not be via wastewater or mixed with household waste. Individuals are instructed to ask a pharmacist how to dispose of the product correctly.